Aliases & Classifications for Paraneoplastic Syndromes

MalaCards integrated aliases for Paraneoplastic Syndromes:

Name: Paraneoplastic Syndromes 51 52 69

Summaries for Paraneoplastic Syndromes

NINDS : 51 Paraneoplastic syndromes are a group of rare disorders that are triggered by an abnormal immune system response to a cancerous tumor known as a "neoplasm." Paraneoplastic syndromes are thought to happen when cancer-fighting antibodies or white blood cells (known as T cells) mistakenly attack normal cells in the nervous system. These disorders typically affect middle-aged to older people and are most common in individuals with lung, ovarian, lymphatic, or breast cancer. Neurologic symptoms generally develop over a period of days to weeks and usually occur prior to the tumor being discovered. These symptoms may include difficulty in walking or swallowing, loss of muscle tone, loss of fine motor coordination, slurred speech, memory loss, vision problems, sleep disturbances, dementia, seizures, sensory loss in the limbs, and vertigo or dizziness. Paraneoplastic syndromes include Lambert-Eaton myasthenic syndrome, stiff-person syndrome, encephalomyelitis, myasthenia gravis, cerebellar degeneration, limbic or brainstem encephalitis, neuromyotonia, opsoclonus, and sensory neuropathy.

MalaCards based summary : Paraneoplastic Syndromes is related to paraneoplastic cerebellar degeneration and lambert-eaton myasthenic syndrome, and has symptoms including paraneoplastic opsoclonus ataxia An important gene associated with Paraneoplastic Syndromes is FGF23 (Fibroblast Growth Factor 23). The drugs Interferon beta-1a and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and bone.

Wikipedia : 72 A paraneoplastic syndrome is a syndrome (a set of signs and symptoms) that is the consequence of cancer... more...

Related Diseases for Paraneoplastic Syndromes

Diseases related to Paraneoplastic Syndromes via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
id Related Disease Score Top Affiliating Genes
1 paraneoplastic cerebellar degeneration 11.3
2 lambert-eaton myasthenic syndrome 11.1
3 poems syndrome 11.1
4 peritonitis 11.1
5 adenoma 11.0
6 autoimmune encephalitis 11.0
7 multicentric reticulohistiocytosis 10.7
8 leiomyoma 10.7
9 leiomyomatosis 10.7
10 carcinoid syndrome 10.7
11 lung cancer 10.2
12 brachydactyly-distal symphalangism syndrome 10.1 IL6 PTHLH
13 ophn1 syndrome 10.0 FGF23 PTHLH
14 polyglucosan body disease, adult form 10.0 FGF23 PTHLH
15 opioid abuse 9.9 FGF23 PTHLH
16 astrakhan spotted fever 9.9 FGF23 PTHLH
17 renal cell carcinoma 9.9
18 lymphoma 9.9
19 squamous cell carcinoma 9.9
20 mild pre-eclampsia 9.9 FGF23 PTHLH
21 breast cancer 9.8
22 parathyroid gland disease 9.8 FGF23 PTHLH
23 hepatocellular carcinoma 9.8
24 thymoma 9.8
25 calcinosis 9.8 FGF23 IL6
26 hyperparathyroidism, familial primary 9.8 FGF23 PTHLH
27 chronic myelomonocytic leukemia 9.8 FGF23 IL6
28 survival motor neuron spinal muscular atrophy 9.8 IL6 PTHLH
29 adenocarcinoma 9.8
30 cerebellar degeneration 9.8
31 leukemia 9.7
32 osteomalacia 9.7
33 neuroblastoma 9.7
34 small cell carcinoma 9.7
35 adult-onset still's disease 9.7
36 prostatitis 9.7
37 acanthosis nigricans 9.7
38 laryngitis 9.7
39 ganglioneuroblastoma 9.7
40 pancreatitis 9.7
41 neuronitis 9.7
42 encephalitis 9.7
43 oral cancer 9.7
44 polymyositis 9.7
45 syndrome of inappropriate antidiuretic hormone 9.7
46 pheochromocytoma 9.6
47 prostate cancer 9.6
48 myasthenia gravis 9.6
49 dermatomyositis 9.6
50 sarcoma 9.6

Graphical network of the top 20 diseases related to Paraneoplastic Syndromes:



Diseases related to Paraneoplastic Syndromes

Symptoms & Phenotypes for Paraneoplastic Syndromes

UMLS symptoms related to Paraneoplastic Syndromes:


paraneoplastic opsoclonus ataxia

Drugs & Therapeutics for Paraneoplastic Syndromes

Drugs for Paraneoplastic Syndromes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
2
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
3
Dexlansoprazole Approved Phase 4 138530-94-6, 103577-45-3 9578005
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
6 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
7 Adjuvants, Immunologic Phase 4
8 Anti-Infective Agents Phase 4,Phase 2
9 Antiviral Agents Phase 4,Phase 2
10 Interferon-beta Phase 4
11 interferons Phase 4,Phase 2
12 Analgesics Phase 4
13 Topoisomerase Inhibitors Phase 4,Phase 2
14 Antacids Phase 4,Phase 3,Phase 2
15 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
16
Proton pump inhibitors Phase 4,Phase 3,Phase 2
17
Zoledronic acid Approved Phase 3,Phase 1,Phase 2 118072-93-8 68740
18
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
21
4-Aminopyridine Approved Phase 3,Phase 2 504-24-5 1727
22
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 4594 9579578
23
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
25 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2
26 Diphosphonates Phase 3,Phase 1,Phase 2
27 Ibandronic acid Phase 3
28 Antiemetics Phase 3
29 Anti-Inflammatory Agents Phase 3
30 Autonomic Agents Phase 3,Phase 1,Phase 2
31 glucocorticoids Phase 3,Phase 1
32 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
33 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
35 Methylprednisolone acetate Phase 3
36 Methylprednisolone Hemisuccinate Phase 3
37 Neuroprotective Agents Phase 3
38 Prednisolone acetate Phase 3
39 Prednisolone hemisuccinate Phase 3
40 Prednisolone phosphate Phase 3
41 Protective Agents Phase 3
42 Antirheumatic Agents Phase 3,Phase 2,Phase 1
43 3,4-diaminopyridine Phase 3,Phase 2
44 Potassium Channel Blockers Phase 3,Phase 2
45 Antineoplastic Agents, Hormonal Phase 3,Phase 2
46 Immunosuppressive Agents Phase 3,Phase 2
47 Antibodies Phase 3,Phase 1,Phase 2
48 Immunoglobulins Phase 3,Phase 1,Phase 2
49 Alkylating Agents Phase 3,Phase 1
50 BB 1101 Phase 3

Interventional clinical trials:

(show top 50) (show all 74)

id Name Status NCT ID Phase Drugs
1 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
2 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
3 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
4 Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer Unknown status NCT00326820 Phase 3 ibandronate sodium;zoledronic acid;Zolendronic Acid
5 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
6 Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone Completed NCT00003884 Phase 3 zoledronic acid
7 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
8 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
9 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
10 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Recruiting NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
11 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes Recruiting NCT02562066 Phase 3 amifampridine phosphate;Placebo
12 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone Withdrawn NCT00301886 Phase 3 ibandronate;zoledronate
15 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2 Ephedrine
16 Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Unknown status NCT00202930 Phase 2 anti-CD20 (Rituximab)
17 Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases Completed NCT00060138 Phase 1, Phase 2 zoledronic acid
18 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome Completed NCT01511978 Phase 2 Continuous 3,4-DAP;Taper 3,4-DAP to Placebo
19 MC-5A for Chemotherapy Induced Peripheral Neuropathy Completed NCT01261780 Phase 2 Sham device
20 Effectiveness of Rituximab in Pediatric OMS Patients. Completed NCT00244361 Phase 1, Phase 2 rituximab
21 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Completed NCT00896454 Phase 2 denosumab
22 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
23 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
24 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
25 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2 Osilodrostat
26 SOM230 Ectopic ACTH-producing Tumors Recruiting NCT02780882 Phase 2 Pasireotide
27 Immunotherapy and Paraneoplastic Neurological Syndromes Active, not recruiting NCT02343211 Phase 2 Immunoglobulin
28 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Active, not recruiting NCT02166346 Phase 2 Dalfampridine;Placebo
29 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
30 Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis Not yet recruiting NCT03274375 Phase 2 IA session;Rituximab
31 IVIG Treatment for Refractory Immune-Related Adult Epilepsy Terminated NCT01545518 Phase 2 IVIG
32 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
33 Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Completed NCT01203592 Phase 1 Albuterol
34 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
35 Central Pain Study for ABX-1431 Recruiting NCT03138421 Phase 1 ABX-1431 HCl;Placebo
36 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
37 One Week Comparison Study of PTH and PTHrP Infusions Withdrawn NCT01333267 Phase 1 Parathyroid Hormone-related Protein (1-36);parathyroid hormone (1-34);PTH (1-34) and PTHrP (1-36)
38 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
39 Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone Unknown status NCT00458796 zoledronic acid
40 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China Unknown status NCT02559089
41 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area Unknown status NCT02443350
42 Immunotherapy of the Paraneoplastic Syndromes Completed NCT00378326 Tacrolimus
43 Studies of Neurological Paraneoplastic Syndromes Completed NCT00587106
44 Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome Completed NCT00806182
45 One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study Completed NCT00580788 Early Phase 1 PTHrP (1-36)
46 Pregnancy Outcomes in Congenital Myasthenie Syndrome Completed NCT01474980
47 Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Completed NCT00004832 3,4-diaminopyridine
48 Clinical Trial of a Serious Game for Individuals With SCI/D Completed NCT02341950
49 Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis Completed NCT01865578
50 Treatment of Zollinger-Ellison Syndrome Completed NCT00001241

Search NIH Clinical Center for Paraneoplastic Syndromes

Genetic Tests for Paraneoplastic Syndromes

Anatomical Context for Paraneoplastic Syndromes

MalaCards organs/tissues related to Paraneoplastic Syndromes:

39
Lung, T Cells, Bone, Eye, Pancreas, Colon, Prostate

Publications for Paraneoplastic Syndromes

Articles related to Paraneoplastic Syndromes:

(show top 50) (show all 424)
id Title Authors Year
1
Rheumatic paraneoplastic syndromes - A clinical link between malignancy and autoimmunity. ( 28736272 )
2017
2
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. ( 28285683 )
2017
3
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes. ( 28285701 )
2017
4
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. ( 28838388 )
2017
5
Alopecia areata as a paraneoplastic syndrome of gastric cancer. ( 27990839 )
2017
6
Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes. ( 28160197 )
2017
7
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions. ( 28838389 )
2017
8
Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. ( 28767671 )
2017
9
Paraneoplastic syndromes associated with gynecological cancers: A systematic review. ( 28655412 )
2017
10
Endocrine perturbations in POEMS syndrome: Misunderstood features of a rare paraneoplastic syndrome. ( 28495325 )
2017
11
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. ( 28285700 )
2017
12
Caution is Needed in Diagnosing IgG4-Related Disease: A Possible Paraneoplastic Syndrome. ( 27863169 )
2016
13
Tumour-induced osteomalacia: An emergent paraneoplastic syndrome. ( 26718193 )
2016
14
Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. ( 26666237 )
2016
15
Autoantibody diversity in paraneoplastic syndromes and related disorders: The need for a more guided screening approach. ( 27287529 )
2016
16
Laryngeal carcinoma presenting as polymyositis: A paraneoplastic syndrome. ( 27011653 )
2016
17
Reply to: "Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients": By BetA1l Vatankulu, Sabire Yilmaz Aksoy, Sait Sager, Metin HalaAs. ( 26669307 )
2016
18
Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. ( 27177440 )
2016
19
Papilledema secondary to a superior sagittal sinus thrombosis. Mantle cell lymphoma paraneoplastic syndrome. ( 26596713 )
2016
20
Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes. ( 26711581 )
2016
21
Intermittent Fever, Progressive Weight Gain, and Personality Changes in a Five-Year-Old Girl: Unusual Paraneoplastic Syndrome due to Presacral Ganglioneuroma. ( 27413558 )
2016
22
Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. ( 26914818 )
2016
23
Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting Manifestation. ( 27293921 )
2016
24
The lung cancer nurse role in the management of paraneoplastic syndromes in lung cancer. ( 27413699 )
2016
25
Paraneoplastic syndromes revealing ovarian teratoma in young and menopausal women: report of two cases. ( 27795759 )
2016
26
A case of acanthosis nigricans as a paraneoplastic syndrome with squamous cell lung cancer. ( 27536145 )
2016
27
Aggressive cervical neuroblastoma with a rare paraneoplastic syndrome: A therapeutic dilemma. ( 27695211 )
2016
28
Severe Hyponatremia Presenting as Paraneoplastic Syndrome in a Patient with Small Cell Carcinoma of Gallbladder. ( 27225161 )
2016
29
Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia. ( 26507447 )
2015
30
Update on neurological paraneoplastic syndromes. ( 26335665 )
2015
31
Paraneoplastic syndrome: a masquerade of autoimmune inner ear disease. ( 25427223 )
2015
32
Piriform sinus carcinoma with a paraneoplastic syndrome misdiagnosed as adult onset Still's disease: a case report. ( 26770614 )
2015
33
Eosinophilic esophagitis as paraneoplastic syndrome in a patient with ganglioneuroblastoma. ( 25985452 )
2015
34
A rare thymoma case with seven paraneoplastic syndromes. ( 26770603 )
2015
35
Different Kinds of Paraneoplastic Syndromes in Childhood Neuroblastoma. ( 26199695 )
2015
36
Paraneoplastic syndromes: the way to an early diagnosis of lung cancer. ( 26506668 )
2015
37
Paraneoplastic Syndromes in Palliative Care: A literature review from a nursing perspective. ( 26514024 )
2015
38
Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS syndrome): a paraneoplastic syndrome. ( 26634133 )
2015
39
Bicytopenia as a paraneoplastic syndrome for pseudomyxoma peritonei. Hematologic manifestations of a subtle disease. ( 25767403 )
2015
40
Paraneoplastic syndromes in olfactory neuroblastoma. ( 26199564 )
2015
41
Paraneoplastic Syndromes in Neuro-Ophthalmology. ( 26172160 )
2015
42
A rare case of severe myositis as paraneoplastic syndrome on breast cancer. ( 25890160 )
2015
43
Resolution of hypercalcemia of malignancy following radical cystectomy in a patient with paraneoplastic syndrome associated with urothelial carcinoma of the bladder. ( 25657552 )
2015
44
Cerebellar Degeneration as a Rare Paraneoplastic Syndrome in a Child With Hodgkin Lymphoma. ( 26599987 )
2015
45
Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes. ( 25829659 )
2015
46
Paraneoplastic Syndrome of Angiomatoid Fibrous Histiocytoma May Be Caused by EWSR1-CREB1 Fusion-induced Excessive Interleukin-6 Production. ( 26165403 )
2015
47
Leukemoid reaction as a paraneoplastic syndrome in hypopharyngeal squamous cell carcinoma with cutaneous metastasis: an exceedingly rare occurrence. ( 26670890 )
2015
48
Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. ( 26194717 )
2015
49
Membranous glomerulonephritis as a novel paraneoplastic syndrome in a young man with chronic myeloid leukemia. ( 26062944 )
2015
50
Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature. ( 24525268 )
2014

Variations for Paraneoplastic Syndromes

Expression for Paraneoplastic Syndromes

Search GEO for disease gene expression data for Paraneoplastic Syndromes.

Pathways for Paraneoplastic Syndromes

GO Terms for Paraneoplastic Syndromes

Biological processes related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 8.96 FGF23 IL6
2 negative regulation of hormone secretion GO:0046888 8.62 FGF23 IL6

Molecular functions related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 8.62 FGF23 IL6

Sources for Paraneoplastic Syndromes

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....